ReviewGene therapy for epilepsy

- Gene therapy may represent an alternative to drugs for some forms of epilepsy.
- The best candidates for this approach appear to be focal epilepsies.
- Gene therapy has been used to produce antiepileptogenic and antiseizure effects.
- Supplementing BDNF and FGF-2 produces putatively antiepileptogenic effects.
- Supplementing galanin or neuropeptide Y produces robust antiseizure effects.

Gene therapy may represent an effective alternative to standard pharmacological approaches for certain forms of epilepsy. Currently, the best candidates for this therapeutic approach appear to be epilepsies characterized by a focal lesion. Gene therapy has been attempted to produce antiepileptogenic (prevention of development of epilepsy in subject at risk after having received an epileptogenic insult), antiseizure (reduction of frequency and/or severity of seizures), and disease-modifying (alteration of the natural history of the disease) effects. An example of gene therapy aimed at producing antiepileptogenic effects is a combination therapy based on the supplementation of the neurotrophic factors brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 2 (FGF-2). Antiseizure effects have been obtained by increasing the strength of inhibitory signals (by supplementing specific GABAA receptor subunits or inhibitory neuropeptides like galanin or neuropeptide Y) or by reducing the strength of excitatory signals (by knocking down NMDA receptor subunits). This review summarizes the results obtained to date using gene therapy in epilepsy models and discusses the challenges and the opportunities that this approach can offer for the treatment of human epilepsies.This article is part of a Special Issue entitled “NEWroscience 2013”.